Biotech giant Regeneron Pharmaceuticals, Inc. REGN is slated to report first-quarter 2025 results on April 29, 2025. The ...

Approval based on Phase 3 trials demonstrating Dupixent significantly reduced itch and hives compared to placebo In the U.S., there are more than ...

Analysts' evaluations of 12-month price targets offer additional insights, showcasing an average target of $831.43, with a high estimate of $1013.00 and a low estimate of $547.00. Highlighting a 8.86% ...

Sanofi India Limited announced on Wednesday that its Managing Director, Rodolfo Hrosz, will step down from his role effective April 30, 2025, to take up another position within the Sanofi group, the ...

Credit: Kateryna Kon / Shutterstock. At the American Academy of Neurology (AAN) 2025 Annual Meeting Clinical Trials Plenary Session, Sanofi presented data on tolebrutinib in patients with ...

Tolebrutinib phase 3 data published in NEJM demonstrate benefit on disability progression in multiple sclerosis Results from the HERCULES phase 3 study showed delay in disability progression in ...

Try Now>> See the top stocks recommended by analysts >> Read More on SNY: Disclaimer & Disclosure Report an Issue Sanofi NewsMORE Related Stocks Indices Commodities Currencies Stocks ...

On 7 April, Dalal Street saw a dramatic downturn as widespread panic-selling caused a steep decline in market valuations. A staggering ₹16 lakh crore in market value was wiped out—the most ...

Arab Finance: Egypt signed four cooperation agreements with Sanofi and the Gustave Roussy Institute to enhance healthcare services and strengthen Egyptian-French collaboration in the health sector, as ...

Supported by Sanofi. Disclosure forms provided by the authors are available with the full text of this article at NEJM.org. We thank the trial participants and their families and caregivers ...